Corcept Therapeutics (CORT)

These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.

Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today

By William White, InvestorPlace Writer Nov 19, 2020

Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB.

7 Great Biotech Stocks to Buy and Hold Now

By Chris Markoch, InvestorPlace Contributor Jun 11, 2020

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer May 18, 2018

The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

10 Healthcare Stocks to Stave Off the Market Flu

By Louis Navellier, Editor, Growth Investor Apr 6, 2018

One thing is certain, healthcare isn’t going away.

Plains GP Holdings LP (PAGP) and Green Plains Inc (GPRE) Lead Today’s Top 11 Investor Filings

By Fintel Jun 15, 2017

13D and 13G filings are windows on activist investor activity. Today we focus on Plains GP Holdings LP, Green Plains Inc and 9 other filings

7 Healthcare Stocks With A-Rated Prospects

By Louis Navellier, Editor, Growth Investor Apr 21, 2017

An Obamacare replacement is back in the news, and these seven A-rated healthcare stocks are winners regardless of how it shakes out.

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

From Chartmill Apr 19, 2024

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

From Chartmill Mar 29, 2024

In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition.

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

From Chartmill Mar 7, 2024

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

Corcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

From Seeking Alpha Feb 15, 2024

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

From Chartmill Feb 14, 2024

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

From Chartmill Jan 24, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.

Corcept Therapeutics (CORT)

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

7 Undervalued Biotech Stocks to Buy Before They Boom

Our 7 Top Biotech Stock Picks for 2023

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Corcept Therapeutics (CORT)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CORT Stock Predictions, Articles, and Corcept Therapeutics News

Subscriber Sign in